Corvus Pharmaceuticals (CRVS) Projected to Post Earnings on Tuesday

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.12) per share for the quarter.

Corvus Pharmaceuticals Trading Down 2.8 %

Corvus Pharmaceuticals stock traded down $0.13 during trading on Thursday, hitting $4.50. 255,234 shares of the company were exchanged, compared to its average volume of 556,207. The business's 50 day moving average is $4.89 and its 200 day moving average is $6.06. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00. The company has a market capitalization of $289.16 million, a P/E ratio of -4.84 and a beta of 0.91.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Oppenheimer upped their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $12.38.

Remove Ads

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.